Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: Final results of a phase III trial

Journal of Clinical Oncology

Volumn 30, Issue 17, 2012, Pages 2055-2062

  Socinski, Mark A ^a   Bondarenko, Igor ^b   Karaseva, Nina A ^c   Makhson, Anatoly M ^d   Vynnychenko, Igor ^c   Okamoto, Isamu ^e   Hon, Jeremy K ^f   Hirsh, Vera ^g   Bhar, Paul ^h   Zhang, Hui ^h   Iglesias, Jose L ^h   Renschler, Markus F ^h  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b Municipal Clinical Hospital #4   (Ukraine)

^c SUMY STATE UNIVERSITY   (Ukraine)

^d City Clinical Oncology Center   (Russian Federation)

^e KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f Clearview Cancer Institute   (United States)

^g MCGILL UNIVERSITY   (Canada)

^h CELGENE CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN BOUND PACLITAXEL; CARBOPLATIN; PACLITAXEL; SOLVENT BASED PACLITAXEL; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; CANCER STAGING; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SENSORY NEUROPATHY; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ALBUMINS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL; SOLVENTS; TREATMENT OUTCOME;

EID: 84863957748     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.39.5848     Document Type: Article

References (26)

1. American Cancer Society: Lung Cancer (Nonsmall cell), 2012, pp 1-68. http://www.cancer.org/acs/groups/cid/documents/webcontent/003115-pdf.pdf
2. American Cancer Society: Cancer Facts and Figures 2011, pp 1-60. http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/ document/acspc-029771.pdf
3. Ettinger D, Akerley W, Borghaei H, et al: NCCN clinical practice guidelines in oncology: Nonsmall cell lung cancer, 2011, pp 1-101
4. Schiller JH, Harrington D, Belani CP, et al: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92-98, 2002 (Pubitemid 34438899)
5. Scagliotti GV, Parikh P, von Pawel J, et al: Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapynaive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26:3543-3551, 2008
6. Eli Lilly: Alimta prescribing information, 2011. http://pi.lilly.com/us/ alimta-pi.pdf
7. Jett JR, Schild SE, Keith RL, et al: Treatment of non-small cell lung cancer, stage IIIB: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 132:266S-276S, 2007 (Pubitemid 47502812)
8. National Institute for Clinical Excellence: The diagnosis and treatment of lung cancer. Clinical Guideline 24:1-41, 2005
9. Kelly K, Crowley J, Bunn PA Jr, et al: Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: A Southwest Oncology Group trial. J Clin Oncol 19:3210-3218, 2001 (Pubitemid 32591438)
10. Sandler A, Gray R, Perry MC, et al: Paclitaxelcarboplatin alone or with bevacizumab for non-smallcell lung cancer. N Engl J Med 355:2542-2550, 2006 (Pubitemid 44917502)
11. Scagliotti G, Novello S, von Pawel J, et al: Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J Clin Oncol 28:1835-1842, 2010
12. Lilenbaum RC, Herndon JE 2nd, List MA, et al: Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: The Cancer and Leukemia Group B (study 9730). J Clin Oncol 23:190-196, 2005 (Pubitemid 41702638)
13. Desai N, Trieu V, Yao Z, et al: Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophorfree, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res 12:1317-1324, 2006 (Pubitemid 43342524)
14. Gradishar WJ, Tjulandin S, Davidson N, et al: Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 23:7794-7803, 2005 (Pubitemid 46657376)
15. Socinski MA, Manikhas GM, Stroyakovsky DL, et al: A dose finding study of weekly and every-3-week nab-Paclitaxel followed by carboplatin as first-line therapy in patients with advanced nonsmall cell lung cancer. J Thorac Oncol 5:852-861, 2010
16. [No authors listed]: Good clinical practice research guidelines reviewed, emphasis given to responsibilities of investigators: Second article in a series. J Oncol Pract 4:233-235, 2008
17. Greene FL, Page DL, Fleming ID, et al: American Joint Committee on Cancer (AJCC) Cancer Staging Handbook (ed 6). New York, NY, Springer, 2002, pp 191-203
18. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
19. van Warmerdam LJ, Rodenhuis S, ten Bokkel Huinink WW, et al: The use of the Calvert formula to determine the optimal carboplatin dosage. J Cancer Res Clin Oncol 121:478-486, 1995
20. Haybittle J: Repeated assessment of results in clinical trials of cancer treatment. Br J Radiol 44:793-797, 1971
21. Peto R, Pike MC, Armitage P, et al: Design and analysis of randomized clinical trials requiring prolonged observation of each patient: II. Analysis and examples. Br J Cancer 35:1-39, 1977 (Pubitemid 8018922)
22. Hommel G: A stagewise rejective mulitple test procedure based on a modified Bonferroni test. Biometrika 75:383-386, 1988
23. Belani CP, Ramalingam S, Perry MC, et al: Randomized, phase III study of weekly paclitaxel in combination with carboplatin versus standard every-3-weeks administration of carboplatin and paclitaxel for patients with previously untreated advanced non-small-cell lung cancer. J Clin Oncol 26:468-473, 2008 (Pubitemid 351171701)
24. Cella D, Peterman A, Hudgens S, et al: Measuring the side effects of taxane therapy in oncology: The functional assessment of cancer therapy-taxane (FACT-taxane). Cancer 98:822-831, 2003 (Pubitemid 36959280)
25. Scripture CD, Figg WD, Sparreboom A: Peripheral neuropathy induced by paclitaxel: Recent insights and future perspectives. Curr Neuropharmacol 4:165-172, 2006
26. Authier N, Gillet JP, Fialip J, et al: Assessment of neurotoxicity following repeated cremophor/ethanol injections in rats. Neurotox Res 3:301-306, 2001 (Pubitemid 32962892)